Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Accumulated Depreciation (2016 - 2025)

Protara Therapeutics' Accumulated Depreciation history spans 10 years, with the latest figure at $1.5 million for Q4 2025.

  • Quarterly Accumulated Depreciation rose 32.73% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 32.73% year-over-year, with the annual reading at $1.5 million for FY2025, 32.73% up from the prior year.
  • Accumulated Depreciation came in at $1.5 million for Q4 2025, up from $1.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $1.5 million in Q4 2025 to a low of $824000.0 in Q4 2023.
  • The 3-year median for Accumulated Depreciation is $1.1 million (2024), against an average of $1.1 million.
  • Year-over-year, Accumulated Depreciation skyrocketed 34.22% in 2024 and then surged 32.73% in 2025.
  • Protara Therapeutics' Accumulated Depreciation stood at $824000.0 in 2023, then surged by 34.22% to $1.1 million in 2024, then soared by 32.73% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for TARA's Accumulated Depreciation are $1.5 million (Q4 2025), $1.1 million (Q4 2024), and $824000.0 (Q4 2023).